EveryONE Medicines
EveryONE Medicines is pioneering a scalable, global framework to design, develop, and manufacture individualized medicines for children with life-threatening neurodegenerative diseases. They focus on antisense oligonucleotides (ASOs) and utilize AI-driven design to create personalized therapies targeting genetic variants. The company aims to create a future where individualized treatment is scaled, sustainable, and accessible, working closely with regulatory agencies, treatment centers, and diagnostic firms to accelerate development and approval processes.
Industries
Nr. of Employees
small (1-50)
EveryONE Medicines
501 Boylston Street, 10th Floor, Boston, MA 02116
Products
Library of individualized antisense therapies
A curated and growing collection of antisense oligonucleotide candidates designed to address ASO-amenable genetic variants, intended to enable rapid matching of patients to candidate therapies.
Library of individualized antisense therapies
A curated and growing collection of antisense oligonucleotide candidates designed to address ASO-amenable genetic variants, intended to enable rapid matching of patients to candidate therapies.
Services
Design and develop patient-specific antisense oligonucleotide candidates using AI-enabled design and translational assays.
Design and operationalize pivotal and early-stage clinical studies that accommodate multiple individualized therapies and ultra-rare patient populations.
Identification of potential patients for individualized therapies by analyzing healthcare records through AI case-finding platforms via strategic partnerships.
Design and develop patient-specific antisense oligonucleotide candidates using AI-enabled design and translational assays.
Design and operationalize pivotal and early-stage clinical studies that accommodate multiple individualized therapies and ultra-rare patient populations.
Identification of potential patients for individualized therapies by analyzing healthcare records through AI case-finding platforms via strategic partnerships.
Expertise Areas
- Individualized antisense therapeutics
- ASO design and library development
- Preclinical assay development and translational testing
- Bioinformatics and genomic analysis
Key Technologies
- Antisense oligonucleotides (ASOs)
- AI-driven sequence analysis and design algorithms
- Next-generation sequencing and single-cell sequencing
- Genomic data mining and bioinformatics
News & Updates
A strategic partnership to enable patients in the UK to have timely access to innovative treatments, leveraging Mendelian’s AI platform to analyze patient data and identify individuals who may benefit from EveryONE Medicines' treatments.
An article discussing the need for new pathways for approval of medicines treating rare conditions, and the role of genetic surgery.
Announcement of Dr. Mellion's appointment to lead clinical trials and oversee the development of personalized medicines.
A report on the UK’s strategy for rare diseases, relevant to EveryONE Medicines’ work.
An article on the development of personalized antisense oligonucleotides for rare diseases.
Discussion on the business aspects of personalized genetic medicines.
A strategic partnership to enable patients in the UK to have timely access to innovative treatments, leveraging Mendelian’s AI platform to analyze patient data and identify individuals who may benefit from EveryONE Medicines' treatments.
An article discussing the need for new pathways for approval of medicines treating rare conditions, and the role of genetic surgery.
Announcement of Dr. Mellion's appointment to lead clinical trials and oversee the development of personalized medicines.
A report on the UK’s strategy for rare diseases, relevant to EveryONE Medicines’ work.
An article on the development of personalized antisense oligonucleotides for rare diseases.
Discussion on the business aspects of personalized genetic medicines.